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Abstract  
Objective: Anorexia nervosa (AN) in adults has poor outcomes and treatment 
evidence is limited. This study evaluated the efficacy and acceptability of a novel, 
targeted psychological therapy for AN (Maudsley Model of Anorexia Nervosa 
Treatment for Adults; MANTRA) compared to Specialist Supportive Clinical 
Management (SSCM). 
Method: 142 out-patients with broadly defined AN (body mass index (BMI)  < 18.5 
kg/m2) were randomly allocated to receive either 20 to 30 weekly sessions (depending 
on clinical severity) plus add-ons (4 follow-up sessions, optional sessions with 
dietician and with carers) of MANTRA (n=72) or SSCM (n=70). Assessments were 
administered blind to treatment condition at baseline, 6 months and 12 months after 
randomization. The primary outcome was BMI at 12 months. Secondary outcomes 
included eating disorders symptomatology, other psychopathology, neuro- and social 
cognition and acceptability. Additional service utilization was also assessed. 
Outcomes were analyzed using linear mixed models.  
Results: Both treatments resulted in significant improvements in BMI and reductions 
in ED symptomatology, distress levels and clinical impairment over time with no 
statistically significant difference between groups at either 6 or 12 months.  
Improvements in neuro- and social-cognitive measures over time were less consistent. 
One SSCM patient died during treatment. Compared to SSCM, MANTRA patients 
rated their treatment as significantly more acceptable and credible at 12 months. 
There was no significant difference between groups in additional service 
consumption. 
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Conclusions: Both treatments appear to have value as first line out-patient 
interventions for patients with broadly defined AN. Longer term outcomes remain to 
be evaluated. 
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Public Health Significance Statements 
This study shows that both MANTRA and SSCM  have promise as first line out-
patient treatments of AN in adults. MANTRA, a novel, targeted treatment based on 
experimental medicine principles, may have  advantages in terms of overall 
acceptability and credibility, and weight outcomes in more severely ill patients.    
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Introduction: 
Anorexia nervosa (AN) in adults, is one of the most difficult psychiatric disorders to 
treat and study (Fairburn et al., 2013; Halmi et al., 2005), because of its high risk of 
death or disability and poor motivation for change (Arcelus, Mitchell, Wales & 
Nielsen, 2011; Treasure, Claudino, & Zucker, 2010). Psychological therapies are the 
first-line treatment, yet outcomes are poor, drop-out high and the evidence-base 
limited (DeJong, Broadbent, & Schmidt, 2012; Watson & Bulik, 2013). A recent 
landmark randomized controlled trial (RCT) of psychological therapies in adult AN 
outpatients found comparable outcomes with focal psychodynamic therapy, enhanced 
cognitive behavioral therapy (CBT-E) and optimized treatment as usual (TAU) (Zipfel 
et al., 2014), confirming the absence of a leading treatment.  
 
There is widespread agreement that new interventions are needed for adults with AN 
and that to improve outcomes such interventions should be theory-based, and targeted 
to specific characteristics and maintaining factors of the disorder (Agras et al., 2004; 
NICE, 2004).  Such a focus on ‘experimental therapeutics’ allows interventions to be 
used ‘as probes of disease mechanisms as well as tests of efficacy (Insel & Gogtay, 
2014; Holmes, Craske & Graybiel, 2014).  With this in mind, we designed a novel 
manual-based out-patient treatment specifically for adults with AN (MANTRA, 
Maudsley Model of Anorexia Nervosa Treatment for Adults) (Schmidt & Treasure, 
2006; Schmidt, Wade, & Treasure, 2014). The development, model, underpinning 
experimental and clinical research and content of this treatment have been described 
elsewhere (Schmidt & Treasure, 2006; Schmidt et al., 2014; Wade, Treasure & 
Schmidt, 2011; Schmidt et al., 2012; Treasure & Schmidt, 2014). MANTRA has 
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shown promise in pilot studies (Wade et al., 2011; Schmidt et al., 2012) and the 
present study is the first large-scale evaluation of this treatment. 
 
One key question in any psychotherapy trial is which comparison therapy to use. 
Arguably, in a potentially lethal disorder such as AN use of a waiting list, or of a 
minimalist psychological placebo/attention control intervention is ethically and 
practically problematic. Use of TAU as a comparison is also not straightforward, 
unless this is standardized. We therefore decided to use Specialist Supportive Clinical 
Management (SSCM), a manualized form of TAU, which has a key focus on 
improving patients’ nutritional health as a prerequisite for recovery. It is delivered in a 
patient-centered, supportive and authoritative manner by experts, familiar with 
managing AN and associated risks. SSCM was designed as a credible and ethical 
control treatment in an RCT in adult out-patients with AN (McIntosh et al., 2005; 
McIntosh et al., 2006). In this study, at end of treatment SSCM was superior in the 
intention to treat (ITT) analysis to one of the active therapies it was compared against 
(interpersonal therapy (IPT)). In the completer analysis, it was superior to both IPT 
and CBT, although in the longer term these effects diminished (Carter et al., 2011). 
Since then, SSCM has been used in one further trial in adults with longstanding AN 
(Touyz et al., 2013). Here, it was as effective as CBT at end of treatment, but 
somewhat worse than CBT at follow-up. 
 
The aim of the present study (MOSAIC trial) was to evaluate the efficacy of 
MANTRA compared to SSCM in a multi-center two-arm superiority RCT of adult 
outpatients with AN. The main hypothesis was that MANTRA would be superior to 
SSCM in terms of weight gain and other outcomes at 6 and 12 months.  
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Method: 
Full details of the MOSAIC trial design and methodology have been described 
elsewhere (Schmidt et al., 2013).  
 
Outcomes were assessed by researchers blind to group allocation at baseline, 6 
months and 12 months after randomization.  The randomization was conducted 
independently by the King’s Clinical Trials Unit and employed  minimization with  
stratifiers: (1) body mass index (BMI) below or above 15 kg/m2, (2) AN-subtype 
(restricting or binge/purge) and (3) previous ED inpatient admission. Ethical approval 
for the trial was obtained from Central London Research Ethics Committee (REC) 4, 
Royal Free Hospital, London, National Health Service (NHS) REC Reference: 
10/H0714/9. 
The trial is registered with Current Controlled Trials: ISRCTN67720902 (URL: 
www.controlled-trials.com/ISRCTN67720902). 
 
Participants 
Patients were recruited from four catchment-area based NHS specialist ED services in 
the UK. These were: South London and Maudsley NHS Foundation Trust (SLaM); 
North East London Foundation Trust Eating Disorders Service (NELFT); Barnet, 
Enfield & Haringey Mental Health NHS Trust (BEH); Oxford Health NHS 
Foundation Trust. Consecutive out-patients referred to these services by their general 
practitioner were offered participation if they were aged between 18 and 60 years, had 
a DSM-IV-TR [2000] diagnosis of AN or Eating Disorder Not Otherwise Specified 
(EDNOS)  and a BMI of 18.5 kg/m2 or below. Our definition of EDNOS was based 
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on that by Thomas, Vartanian & Brownell (2009) and includes people who fulfill all 
criteria of AN, except the weight criterion; those who fulfil all criteria for AN but still 
have menses; those without a fat phobia; and those with partial AN (defined as having 
features of AN but missing at least two of the four diagnostic criteria). We thus 
included patients across the spectrum of illness severity (ranging from mild to severe), 
to reflect a typical adult outpatient population presenting to specialist services.  
Exclusion criteria were: life-threatening AN requiring immediate inpatient treatment 
as defined in the UK NICE guidelines for eating disorders (National Institute for 
Clinical and Health Care Excellence, 2004); insufficient knowledge of English to 
understand the treatment; learning disability; severe mental or physical illness which 
needs treatment in its own right (for example, psychosis or diabetes mellitus); 
substance dependence or pregnancy. We did not exclude patients on antidepressants, 
provided they were on a stable dose, for at least four weeks. 
 
Care was taken to introduce the study to potential participants in a standardized way 
and to maintain equipoise between both treatments and present them as equal. A 
recruitment DVD demonstrating this was produced to train clinicians and researchers 
in the recruitment process. After complete description of the study to potential 
participants, written informed consent was obtained.  
 
Treatments 
Commonalities between treatments 
In both treatments, patients received 20 once-weekly individual therapy sessions and 
four monthly follow-up sessions. In patients with BMI ≤15 kg/m2, weekly treatment 
was extended to 30 sessions. In both treatments two additional sessions with a close 
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other were offered. In addition, participants had access to dietitian sessions (usually 4-
5) as needed, as is usual practice in the UK. Monitoring of physical risk is part of both 
treatments. Therapy sessions are approximately 50 minutes, however in SSCM, from 
the middle stage of treatment, sessions may be reduced to 30 minutes at the therapist’s 
discretion (McIntosh et al., 2005).  
 
MANTRA 
MANTRA is an empirically-based cognitive-interpersonal treatment, which proposes 
that four broad factors, linked to underlying obsessional and anxious/avoidant 
personality traits, are central to the maintenance of AN. These are (1) a thinking style 
characterized by inflexibility, excessive attention to detail, and fear of making 
mistakes; (2) impairments in the socio-emotional domain (e.g. difficulties in emotion 
recognition and Theory of Mind, avoidance of emotional experience and expression); 
(3) positive beliefs about how AN helps the person manage their life and (4) unhelpful 
responses of close others, such as overinvolvement, accommodation to or enabling of 
symptoms, criticism and hostility (Schmidt & Treasure, 2006; Treasure & Schmidt 
2014). These maintenance factors are targeted in treatment with the aim of facilitating 
wider changes in eating disorder symptomatology and weight. Treatment is centred 
around a patient-manual (Schmidt et al., unpublished). There are several core (e.g. 
formulation) and some optional modules (e.g. module on building a ‘non-anorexic’ 
identity designed specifically for patients with very long-standing illness). Treatment 
is formulation-based and has a clear structure and hierarchy of therapeutic procedures. 
Individual tailoring of treatment arises from flexibility as to how components of 
MANTRA are combined and how much emphasis they are given (including e.g. 
optional modules).  
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The therapeutic style is that of motivational interviewing (i.e. patient-centered and 
using reflection strategically to facilitate change). Further details are given elsewhere 
(Schmidt et al., 2012; Schmidt et al., 2013; Schmidt et al., 2014). 
 
SSCM 
This treatment was designed as an active comparison treatment in a clinical trial to be 
delivered by therapists with expertise in the treatment of ED and to provide a 
standardized form of usual out-patient treatment (McIntosh et al., 2005; McIntosh et 
al., 2006). It combines clinical management i.e. giving information, advice, and 
encouragement with a supportive therapeutic style, designed to build a positive 
therapeutic relationship and to foster change.  Therapy content includes assessment, 
identification of and regular review of target symptoms, psychoeducation, monitoring 
of physical status, establishing a goal weight range and nutritional education and 
advice. The aim is to help patients make a link between their clinical symptoms and 
their abnormal eating behavior and weight, and to support patients in a gradual return 
to normal eating and weight. Additional therapy content is determined by the patient. 
Further details are described in McIntosh et al. (2006). A therapist manual (McIntosh 
et al., unpublished) is available with detailed psycho-educational handouts for 
patients. These are used flexibly and as deemed appropriate for a particular patient by 
the therapist. 
 
Therapists 
Twenty-eight experienced ED therapists delivered the treatments. All attended two 
initial training days on MANTRA and two on SSCM and further ‘booster’ training 
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days were held at intervals to avoid therapeutic ‘drift’. Therapists were expected to 
see patients in both conditions, to control for therapist effects. Regular weekly trial 
supervision was provided by experienced supervisors in each team and separately for 
the two treatment conditions, to avoid contamination across therapies. Patients were 
allocated to therapists based on availability. To ensure competent and uniform 
treatment delivery, psychotherapy sessions were audiotaped to be able to assess 
adherence. Formal fidelity analyses of these tapes will be reported separately. As 
afurther fidelity check qualitative interviews of therapists and patients were carried 
out (Waterman-Collins et al., 2014; Lose et al., 2014). These suggested that these 
treatments were delivered as designed.  
 
Management of significant deterioration or failure to improve  
Patients who deteriorated significantly whilst receiving out-patient therapy were 
offered in-patient treatment if they fulfilled criteria for admission (NICE, 2004). 
Those who failed to improve with out-patient treatment were offered day-care.  
 
Assessment 
Outcome measures 
Outcome measures were collected pre-randomization (baseline), and at 6 and 12 
months post randomization. The primary outcome was BMI at 12 months.  
 
ED psychopathology was assessed with the Eating Disorders Examination (EDE) 
Interview (Fairburn, Cooper & O’Connor, 2008). For the small number of patients 
unwilling/unable to complete the EDE interview at follow-up, the questionnaire form 
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of this assessment (EDE-Q) was used instead. The EDE-Q has been found to have 
similar validity to the EDE interview (Fairburn & Beglin, 1994). 
 
General psychopathology was assessed using two measures. We used the Depression, 
Anxiety and Stress Scale - 21 (DASS-21) (Lovibond & Lovibond, 1995), a 21-item 
self-report measure that assesses mood state over the past seven days using a 4-point 
Likert scale. The total score can be used as a measure of general distress. High scores 
indicate higher symptomatology.  This measure has good reliability and validity 
(Brown, Chorpita, Korotitsch, & Barlow, 1997). We also used the Obsessive 
Compulsive Inventory-Revised (OCI) (Foa, Huppert, Leiberg, Langner, Kichic,  
Hajcak, & Salkovskis, 2002). This 18 item questionnaire uses a 5 point forced choice 
severity scale and provides a single global score (max score=72). The measure has 
excellent psychometric properties.   
 
Psychosocial Impairment was assessed using the Clinical Impairment Assessment 
(CIA) (Bohn & Fairburn, 2008), a self-report measure of impairment resulting from 
the individual’s ED. This is a 16- item questionnaire which generates a single global 
score to signify level of impairment. Each item is rated on a 4 point scale (max 
score=48). The CIA has high levels of internal consistency, construct and 
discriminant validity, test-retest reliability, and sensitivity to change. 
 
Treatment credibility and acceptability were assessed with visual analogue scales 
(VAS), rated on a 0 to 10 scale, at 6 and 12 months. These were designed for the 
purpose of the study. 
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Neurocognition and social cognition were assessed using measures of set-shifting 
(Wisconsin Card Sorting Task (Psychological Assessment Resources, 2003), Brixton 
Spatial Anticipation Task, (Burgess & Shallice, 1997)), central coherence (Rey-
Osterrieth Complex Figure Test (Osterrieth, 1944; Rey, 1941)) and Theory of Mind 
(‘Reading the Mind in Film’ task (Golan, Baron-Cohen, Hill, Golan, 2006)).  Scoring 
details are given elsewhere (Renwick et al., 2014). Additional potential mediator 
variables were measured (Schmidt et al., 2013), but will be reported elsewhere. 
 
Sample Size Calculation 
The sample size calculation was based on a mean weight gain of 7.3 kg (standard 
error 0.96 kg) observed in an unpublished series of nine pilot patients treated with 
MANTRA. The mean weight gain for SSCM was previously estimated as 4 kg 
(McIntosh et al. (2005)). We derived a conservative estimate of the group difference 
by a low estimate of the weight gain under MANTRA (mean – 0.8 × standard error = 
6.5 kg) minus the weight gain estimate for SSCM; giving a difference of 2.5 kg.  We 
calculated that a sample size of 55 participants per group would have 90% power to 
detect a difference in mean weight gain of 2.5 kg assuming a common weight gain 
standard deviation of 4 kg (as per an unpublished series of 9 MANTRA patients) and 
using an independent samples t-test with a significance level of 0.05. Correcting for 
20% attrition, a total of 138 patients was needed.  
 
Statistical Analyses 
All statistical analyses were based on the intention-to-treat principle and were carried 
out by statisticians blind to treatment allocation using Stata 12 (StataCorp, 2011). 
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All outcomes were analysed using linear mixed models. The dependent variable was 
the outcome at the respective time point and the (fixed) explanatory variable of 
interest was trial arm. Further covariates for inclusion in the model were chosen a 
priori on the basis that such variables were known to predict outcome (within trial 
arms). Specifically we conditioned on baseline values of the variable under 
investigation and the randomization stratifiers BMI, AN-subtype and previous ED 
inpatient admission (Pocock, Assmann, Enos, & Kasten, 2002). In addition the model 
contained random effects for therapists in the two randomization groups to allow for 
correlation in outcomes due to treatment being facilitated by the same therapist. The 
variance of these random effects was allowed to vary between trial arms by including 
an interaction between therapist and treatment. 
 
Outcome variables contained some missing values. We empirically assessed whether 
a number of baseline variables were predictive of missing values in outcome and also 
checked whether non-adherence to treatment (coded “1”=completed at least 15 
therapy sessions, “0”=did not complete intervention) was predictive of loss to follow-
up; out of these only non-adherence was found to be an empirical predictor (see 
Results). To allow this process to be predictive of missingness, multiple imputation 
(MI) using chained equations was implemented (Stata command ice, (Royston, 
2004)). The imputation step of the procedure used treatment arm, baseline value, 
randomization stratifiers, outcome at other time points, adherence and therapist 
dummy variables to predict missing post-randomization outcome values. Here the 
benefit of MI lies in its ability to incorporate post-randomization variables that are not 
part of the analysis model (treatment non-adherence) in the imputation step and so 
enable an analysis that is valid under a more realistic missing at random (MAR) 
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assumption (Sterne et al., 2009). To minimise Monte-Carlo error, fifty imputations 
were used. Subgroup analyses were used to assess the estimated treatment effects 
amongst those with a baseline BMI below 17.5kg/m2 and amongst treatment 
completers. 
 
Results: 
Participant Flow and Baseline Characteristics  
One hundred and forty-two participants were recruited between June 2010 and 
November 2012 (SLaM: n= 85; NELFT: n=10; BEH: n= 20; Oxford Health: n=27). 
Demographic and clinical characteristics are summarised in Table 1. The two 
treatment arms were reasonably balanced on all baseline characteristics.  
 
Participant flow through the study is shown in Figure 1.  
All 142 participants were included in the primary outcome analysis.  
 
Treatment Uptake, Attendance and Acceptability  
Figure 1 shows treatment uptake and attendance. There was some suggestion that the 
median number of individual therapy sessions attended differed between groups 
(p=0.05). As in SSCM, from the middle stage of treatment, individual therapy 
sessions could be reduced to 30 minutes at the therapist’s discretion, we also 
calculated the mean duration of sessions for each treatment.  In MANTRA (where this 
information was available for n=54 (75%) of participants) the mean session duration 
was 53.1 (4.3) mins, whereas in SSCM (where this information was available for 
n=40 (57%) of participants) the mean session length was 47.4 (6.8) mins. This 
difference was significant (t(92)=4.88, p<0.001). As in other studies, treatment 
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completion was defined a priori as attending >15 therapy sessions, i.e. receiving more 
than 75% of weekly sessions (Zipfel et al., 2014). Seventy-five percent of MANTRA 
and 59% of SSCM participants completed treatment.  One SSCM patient who had a 
very severe chronic illness with multiple previous treatments, died suddenly during 
treatment.  
 
Non-completion of treatment was predictive of loss to follow-up at 12 months. 45.2% 
of non-completing participants compared to 10.5% of completers had missing primary 
outcome data at 12 month follow-up (p<0.001). Web-table 1 gives details. 
 
There were no significant differences in acceptability and credibility ratings between 
MANTRA and SSCM at 6 months (Acceptability: MANTRA=8.5 (2.0), SSSCM= 8.0 
(2.2) [t(100)=1.33, p=0.18], Credibility: MANTRA=6.4 (3.1), SSSCM= 5.8 (2.7) 
[t(100)=1.1, p=0.29]). However, at 12 months MANTRA received significantly 
higher acceptability and credibility ratings than SSCM (Acceptability: MANTRA=8.6 
(1.8), SSCM= 7.8 (2.3) [t(91)=2.01, p=0.047] Credibility: MANTRA=6.8 (3.1), 
SSCM= 5.5 (2.7) [t(91)=2.24, p=0.027]).     
 
Groups did not differ in proportions of participants who had additional sessions with a 
dietician (MANTRA 33/72 (45.83%); SSCM 31/70 (44.29%), χ2(1)=0.03, p=0.85), 
nor in proportions of participants who had sessions with a carer (MANTRA 30/61 
(49.18%); SSCM 31/61 (50.81%), χ2(1)=0.00, p=1.00). The median total number of 
treatment sessions (individual therapy plus dietician sessions plus sessions with a 
carer) was n=23 for MANTRA and n=20 for SSCM (p=0.063). 
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Additional Service Utilization  
Information on additional service utilization during the study period was available for 
67/72 (93.1%) MANTRA and 64/70 (91.4%) SSCM  patients. Eight MANTRA 
patients (11.9%) had additional psychiatric treatment. Five had ED in-patient or day-
care treatment (range 1-217 days). One of these and three others had brief general 
psychiatric treatment (e.g.  for suicidality or alcohol problems).  
 
Ten SSCM patients (15.6%) had additional psychiatric treatment. Eight had ED in-
patient or day-care (2-198 days), one of these and two others also had a general 
psychiatric admission for depression and suicidality.  The difference in proportions of 
patients with additional treatment was not significant (χ2(1)=0.38, p=0.54).  
 
Treatment Outcomes 
No baseline variables were found to be predictive of later missingness. However non-
completion of treatment predicted missingness in that 45.2% of those who were non-
compliant had missing outcome data, whereas this proportion was only 10.5% for 
treatment completers. Table 2 shows estimated group differences at 6 and 12 months. 
Table 3 shows the corresponding estimated means and standard errors, accounting for 
the fact that adherence predicts missingness (using multiple imputation) and allowing 
for therapist effects.   
 
Mean BMI did not differ significantly between groups at either 6 (p=0.39) or 12 
months (p=0.34; primary outcome; see Figure 2). Mean EDE Global score also did 
not differ significantly at either 6 (p=0.62) or 12 months (p=0.30), nor did any of the 
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other secondary outcomes. All associated standardised effect sizes were estimated to 
be small (Cohen’s d  0.30).  
 
Web-Table 2 shows estimated mean outcome change by group and post-
randomization time point. There was a significant improvement in BMI in both 
groups after commencing treatment, with mean BMI in the MANTRA group 
estimated to increase from baseline to month  6 by 1.06 (95% CI 0.55 to 1.57)  and 
from baseline to month 12 by 1.83 (95% CI 1.12 to 2.54). Respective figures in 
SSCM were 0.80 (0.31 to 1.29) and 1.44 (95% CI 0.73 to 2.15). In both groups, there 
was also significant change for EDE Global and subscale scores, DASS-21 and CIA 
scores between baseline and 6 months and baseline and 12 months, whereas OCI-R 
and neuro- and social cognitive measures changed less consistently or not at all.  
 
Recovery Rates 
Our definitions of recovery and partial recovery were based on those previously used 
in other studies (Fairburn et al., 2013) and were as follows: recovered: BMI>18.5 
kg/m2 and EDE Global Score <2.77; partially recovered: BMI<17.5 kg/m2 and 
EDE<2.77 or BMI between >17.5 kg/m2 and ≤18.5 kg/m2 or BMI>18.5 kg/m2 and 
EDE>2.77;  not recovered: BMI≤ 17.5 kg/m2 and EDE>2.77.  Recovery rates by 
group were comparable in those for whom this information was available:  Baseline:  
SSCM: recovered: 0/70; partially recovered: 33/70 (47.14%), not recovered: 37/70 
(52.86%). MANTRA : recovered: 0/72, partially recovered: 39/72 (54.17%), not 
recovered: n=33/72 (45.82%).  6-months:  SSCM: recovered: 7/55  (12.73 %), 
partially recovered: 32/55 (58.18 %), not recovered: 16/55 (29.09 %). MANTRA : 
recovered: 7/63 (11.11 %), partially recovered: 41/63 (65.08 %), not recovered: 15/63 
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(23.81 %). 12-months:  SSCM: recovered: 8/49 (16.33 %), partially recovered: 32/49 
(65.31 %), not recovered: 9/49 (18.37 %). MANTRA : recovered:13/58 (22.41 %), 
partially recovered: 36/58 (62.07 %), not recovered: 9/58 (15.52 %).  
 
Subgroup analyses 
The sample was restricted to those with baseline BMI below 17.5 kg/m2 because our 
pilot study (Schmidt et al., 2012) suggested that MANTRA may be more 
advantageous in more underweight patients (MANTRA: n=56; SSCM: n=49). The 
magnitudes of the group differences in BMI increased at both post-randomization 
time points. At 6 months, the group difference was 0.57 kg/m2 (z=1.70, p=0.09, 95% 
CI -0.09 to 1.22) or 1.23 kg (z=1.26, p=0.21, 95% CI -0.69 to 3.14)  in favor of 
MANTRA. The predicted change in BMI was 1.25 kg/m2 (or 3.08 kg) for those 
offered MANTRA and 0.68 kg/m2 (or 1.85 kg) for those allocated to SSCM. At 12 
months, the BMI difference was 0.70 kg/m2 (z=1.55, p=0.12, 95% CI -0.19 to 1.58) or  
1.51 kg (z=1.21, p=0.23, 95% CI -0.94 to 3.95) in favor of MANTRA. The predicted 
BMI changes were 1.98 kg/m2 (or 5.03 kg) and 1.28 kg/m2 (or 3.52 kg) for those in 
the MANTRA and SSCM groups respectively. 
 
To evaluate effect of treatment receipt, another subgroup analysis included only 
treatment completers (MANTRA n=54, SSCM n=41). In the completers the BMI 
difference at 6 months was 0.33 kg/m2 (z=1.08, p=0.28, 95% CI -0.27 to 0.94) or 0.65 
kg (z=0.71, p=0.48, 95% CI -1.13 to 2.43) and at 12 months was 0.34 kg/m2 (z=0.83, 
p=0.41, 95% CI -0.46 to 1.13)  or 0.66 kg (z=0.59, p=0.56, 95% CI -1.54 to 2.87), all 
in favor of MANTRA. 
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Discussion: 
Participants in both groups improved significantly in BMI, ED psychopathology, 
affective symptoms and psychosocial impairment at both 6 and 12 months post-
randomization, with neuro- and social-cognitive change less consistent. However, our 
main hypothesis was not confirmed as there were no statistically significant 
differences in outcomes between the two treatments.  
 
As per our study design, MANTRA therapy sessions were significantly longer than 
SSCM sessions. In addition, patients receiving MANTRA attended more of their 
scheduled individual therapy sessions than those receiving SSCM. Utilization of 
therapy add-ons (dietician and carer sessions) and of services  outside the study 
treatments were similar in both groups.  
 
On patients’ self-report of treatment acceptability and credibility,  MANTRA was 
rated significantly more favourably on both compared to SSCM at 12 months. 
Subgroup analyses found a trend for more underweight patients receiving MANTRA 
to show greater BMI increase at 6 months (p=0.09) and 12 months (p=0.12).   
 
These findings deserve comment: Firstly, whilst there were some improvements in 
both groups on neuro- and social cognitive measures, these were less clear-cut than 
changes in the other outcome measures. This may be explained by the fact that our 
outpatient sample had a broad range of severity and many patients were not 
particularly impaired on neuro- and social-cognitive measures (Renwick et al., 2014), 
which has previously been highlighted elsewhere (Schmidt et al., 2012; Tchanturia et 
al., 2011). Whilst MANTRA explicitly targets patients’ thinking and socio-emotional 
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style, including e.g. cognitive inflexibility, lack of bigger picture thinking and 
fear/avoidance of emotions and relationships, these features go much beyond 
narrowly defined neuro- or social-cognitive impairments. As such the lack of 
consistent or differential improvement on neuro- and social cognitive variables is not 
surprising.   
 
Secondly, MANTRA patients received a somewhat higher dose of treatment. Group 
differences in treatment dose were in part ‘design driven’ (i.e. shorter SSCM sessions) 
and in part ‘patient-driven’ (MANTRA patients attended more of their scheduled 
therapy sessions). It is possible that some SSCM patients opted not to attend their full 
contingent of scheduled therapy sessions because they were only offered shorter 
sessions during the second half of treatment.  
 
Thirdly, trends for MANTRA to produce better BMI outcomes in more severely ill 
patients are encouraging. Whether these result from differential treatment dose effects 
(including the availability of a treatment manual for reference beyond the scheduled 
sessions), greater acceptability of this treatment per se or specific content targeted 
towards AN maintenance factors remains to be seen.  
 
Fourthly, one death occurred in our trial, in an SSCM patient with longstanding 
severe AN. The highly elevated mortality risk in chronically ill, low-weight AN, has 
been documented (e.g. Arcelus et al., 2011) and previous AN outpatient trials have 
reported deaths (McIntosh et al., 2005; Dare et al., 2001).  
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Our findings also need to be put into context of the wider AN –treatment literature. 
Overall, participant retention in the MOSAIC trial was excellent with 83% and 73% 
of MANTRA and SSCM participants respectively providing BMI and EDE data at 12 
months. In comparison, in the German landmark trial7 between 59% (TAU) and 83% 
(CBT-E) participants provided data at 13 month post-randomization. Treatment 
completion rates (MANTRA: 75%;  SSCM: 59%) also compare well against those of 
similar recent studies (54 to 91%) (Fairburn et al., 2013; Zipfel et al., 2014; McIntosh 
et al., 2005; Dare, Eisler, Russell, Treasure, & Dodge, 2001; Wildes, Marcus, Cheng, 
McCabe, & Gaskill, 2014; Lock et al., 2013).   
 
BMI outcomes from the present study compare well with those of the recent German 
trial (Zipfel et al., 2014) where patients had similar baseline characteristics, but 
received 40 psychotherapy sessions. The degree of improvement in the current trial is 
somewhat better than that in our single-centre pilot RCT of these treatments (Schmidt 
et al., 2012), suggesting that both MANTRA and SSCM can be disseminated with 
relatively brief training of therapists.  
 
Two other RCTs have used SSCM (McIntosh et al., 2005; Touyz et al., 2013). 
Comparison of our data against these trials is difficult, because of differences in 
patient populations, with one focusing on milder, less chronic  (McIntosh et al., 2005) 
and the other on very chronic patients (Touyz et al., 2013).  
 
The MOSAIC trial is the first RCT of AN treatment to include qualitative feedback 
from both patients and therapists. As is recommended, we published this prior to 
outcome evaluation (Waterman-Collins et al., 2014; Lose et al., 2014). Process data 
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from therapists identified major differences in focus, procedures and strengths 
between the two treatments (Waterman-Collins et al., 2014). Data from patients echo 
this, and also highlight the importance of the therapeutic relationship (Lose et al., 
2014). We also examined written qualitative feedback on their experience of therapy 
from all study participants at 12 months (Zainal, unpublished  data). Significantly 
more MANTRA compared to SSCM patients provided positive feedback. Taken 
together with acceptability and credibility ratings these qualitative findings suggest 
that MANTRA is preferred by patients and thus and provides a strong alternative to 
SSCM. Importantly, greater acceptability of MANTRA may translate into greater 
willingness to have further treatment if needed or into better longer-term outcomes.   
 
The study has considerable strengths. It is one of the largest RCTs of first line 
psychological treatments for adult outpatients with AN worldwide. It had excellent 
participant retention, treatment completion and acceptability rates and very good 
outcomes compared to other similar studies. The trial therefore adds to our limited 
knowledge regarding the effective treatment of this population. This study is also the 
first large-scale AN trial to report neuro- and social cognitive outcomes. Furthermore, 
it incorporates a process evaluation, offering insight into patient and therapist 
perceptions of the two treatments. Trial interventions were delivered by therapists 
with different backgrounds and levels of experience, reflecting real life clinical 
practice. The trial also included patients across a broad range of clinical severity.  
 
The study also has several limitations. First, it would probably have been better to 
offer individual therapy sessions of similar length in both treatments as this would 
have made reasons for any differences in attendance and acceptability easier to 
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understand.   Second, although large, the study is still not large enough to perform 
definitive mediation and moderation analyses of the maintenance factors targeted by 
MANTRA and thereby illuminate mechanisms of action. However, MOSAIC trial 
data can be combined with those from our pilot RCT (Schmidt et al., 2012) to do so.  
Third, a further limitation, common to all psychotherapy trials is that neither patients 
nor therapists were blind to treatment allocation. MANTRA was developed in one of 
the participating sites, by investigators involved in the current trial. Despite our best 
efforts not to bias patients or therapists towards or against either of the study 
treatments, we cannot rule out the presence of subtle allegiance effects to MANTRA 
in at least one of the centres (where this treatment was developed). These allegiance 
effects may have manifested e.g. in patients’ perception of greater acceptability and 
credibility of this treatment. Ultimately, independent replication of the study is 
needed, and this is currently in progress in Australia in a multi-centre RCT comparing 
MANTRA, SSCM and CBT-E (Byrne, personal communication).  Fourth, we have 
not as yet completed a formal therapist fidelity analysis. A final limitation is the short 
duration of follow-up. Further follow up is necessary to measure the longer-term 
effects of these two treatments on different outcomes.  This is especially important 
given suggestions that SSCM effects may ‘wash out’ over time (Carter et al., 2011). 
We are currently collecting 2-year follow-up data of MOSAIC patients.  
 
In conclusion, findings from this trial suggest that  both treatments have promise as 
first line out-patient treatments of AN in adults, with MANTRA, a novel, targeted 
treatment based on experimental medicine principles, having advantages in terms of 
overall acceptability and credibility, and possibly also BMI outcomes in more 
severely ill patients.    
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In considering which of these treatments to choose for their patients, clinicians need 
to bear in mind the ‘three-legged stool’ principle of evidence-based medicine 
(Lilenfeld, 2014; Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996). This 
suggests that best available research evidence, clinical expertise and patient 
preference need to all be considered in selecting interventions.  
 
Future studies may want to assess the utility of these treatments against other 
psychological therapies for AN. As mentioned above, comparison of MANTRA and 
SSCM with CBT-E is already in progress. It would also be useful to establish the 
relative efficacy of these treatments for different groups of patients, defined by illness 
severity or duration (e.g. first episode cases versus more established cases).  In 
adolescents or young adults with AN, it may be of interest to evaluate MANTRA as 
an adjunct to family therapy. Finally, with the emergence of novel brain-directed 
treatments, such as neuromodulation and neurofeedback treatments (McClelland,  
Bozhilova, Campbell, & Schmidt, 2013; McClelland, Bozhilova, Nestler, Campbell, 
Jacob, Johnson-Sabine,  & Schmidt, 2013; Bartholdy, Musiat, Campbell & Schmidt, 
2013), attention-bias modification (Renwick, Campbell & Schmidt, 2013), exposure 
treatment (Koskina, Campbell & Schmidt, 2013)  and novel medication strategies 
(Maguire, O'Dell, Touyz, & Russell , 2013) it may be of interest to see whether the 
combination of these with psychological treatments such as MANTRA or SSCM 
leads to improved outcomes in adults with AN.   
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Table 1: Baseline Characteristics of the Sample 
 Whole Group SSCM MANTRA 
Demographic 
details 
N  N  N  
Age, years: Mean 
(SD)  
142 26.7 (7.7) 70 25.9 (7.1) 72 27.5 (8.1) 
Males: Females, n 142 3:139 70 3:67 72 0:72 
Years in Education, 
Mean (SD) 
125 15.8 (2.3) 62 15.5 (2.5) 63 16.1 (2.1) 
In relationship,  
n (%) 
138 50 (35.2 %) 66 29 (41.4) 72 21 (29.2) 
Clinical details       
Diagnosis, n (%) 
AN-R 
AN-BP 
EDNOS 
142  
63 (44.4) 
44 (31.0) 
35 (24.6) 
70  
28 (40) 
22 (31.4) 
20 (28.6) 
72  
35 (48.6) 
22 (30.6) 
15 (20.8) 
BMI, kg/m2, Mean 
(SD) 
142 16.6 (1.2) 70 16.6 (1.3) 72 16.6 (1.2) 
Weight, kg, Mean 
(SD) 
142 45.1 (4.9) 70 45.4 (5.4) 72 44.8 (4.5) 
Age at onset, years, 
Mean (SD) 
132 17.7 (6.5) 65 18.1 (6.6) 67 17.3 (6.5) 
Duration of Illness, 
years, mean (SD) 
134 8.3 (7.3) 67 7.2 (6.5) 67 9.3 (7.9) 
Previous ED 
treatment, n (%)  
140 80 (56.3) 70 39 (55.7) 70 41 (56.9) 
EDE, Mean (SD) 142 3.3 (1.3) 70 3.5 (1.3) 72 3.1 (1.3) 
DASS21, Mean 
(SD)  
138 30.5 (12.7) 69 31.4 
(13.8) 
69 29.6 (11.5) 
OCI-R, Mean (SD) 139 23.6 (13.7) 69 24.9 
(15.1) 
70 22.3 (12.2) 
CIA, mean (SD) 141 32.6 (8.9) 70 33.0 (8.9) 71 32.1 (9.0) 
Current 
antidepressant 
medication, n (%) 
140 55 (38.7) 70 26 (37.1) 70 29 (40.3) 
 
SSCM: Specialist Supportive Clinical Management; MANTRA: Maudsley Model of 
Anorexia Nervosa Treatment for Adults; AN-R, anorexia nervosa restricting type; 
AN-BP, anorexia nervosa binge eating/purging type; EDNOS, eating disorder not 
otherwise specified; BMI, body mass index; EDE, eating disorder examination; 
DASS21, depression anxiety stress scale; OCI-R, Obsessive Compulsive Inventory-
Revised; CIA, clinical impairment assessment.  
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Figure 1: CONSORT Flow Diagram 
Assessed for eligibility (n=319) 
Excluded  (n= 177) 
Not meeting inclusion criteria (n=48) 
 Outside of age limit (n=2) 
 BMI>18.5 (n=34) 
 No current DSMIV diagnosis of AN or EDNOS-AN (n=12) 
Met exclusion criteria (n=33) 
 Alcohol / drug dependence (n=4) 
 Severe mental illness (n=8) 
 Learning disability (n=1) 
 Received MANTRA in past year (n=3) 
 Receiving treatment elsewhere (n=3) 
 Pregnancy (n=1) 
 Severe Physical Risk (n=13) 
Declined to participate (n=73) 
Other reasons (n=23) 
Completed EDE interview: 
Baseline: n = 70/70 (100%) 
6 months: n = 55/70 (79%) 
12 months: n = 51/70 (73%) 
 
Completed BMI assessment: 
Baseline: n = 70/70 (100%) 
6 months: n = 55/70 (79%) 
12 months: n = 51/70 (73%) 
 
Treatment sessions attended  
 Missing: n=3 (4.3%) 
 Did not start treatment: n=6 (8.6%) 
 1-4 sessions: n=3 (4.3%) 
 5-9 sessions: n=12 (17.1%) 
 10-14 sessions: n=5 (7.1%) 
 15-19 sessions: n=12 (17.1%) 
 20-24 sessions: n=22 (31.4%) 
 >25 sessions: n=7 (10%) 
Median no of sessions attended: 18 (0-32) 
 
Treatment sessions attended  
 Missing: n=2 (2.8%) 
 Did not start treatment: n=4 (5.5%) 
 1-4 sessions: n=2 (2.7%) 
 5-9 sessions: n=7 (9.7%) 
 10-14 sessions: n=3 (4.2%) 
 15-19 sessions: n=12 (16.7%) 
 20-24 sessions: n=31 (43.1%) 
 >25 sessions: n=11 (15.2%) 
Median no. of sessions attended: 20 (0-30) 
 
Completed EDE interview: 
Baseline: n = 72/72 (100%) 
6 months: n = 64/72 (89%) 
12 months: n = 60/72 (83%) 
 
Completed BMI assessment: 
Baseline: n = 72/72 (100%) 
6 months: n = 64/72 (89%) 
12 months: n = 60/72 (83%) 
Randomized (n=142) 
Allocated to SSCM (n=70) 
Received allocated intervention: n=68 
Did not receive allocated intervention: n=2 (1 patient 
received MANTRA, 1 patient received Cognitive 
Analytical Therapy)  
 
Allocated to MANTRA (n=72) 
Received allocated intervention: n=71 
Did not receive allocated intervention: n=1 (received 
mixture of CBT and MANTRA) 
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Figure  2. Predicted mean BMI at both post-randomization time points (originating 
from observed mean at baseline). Covariates were fixed at mean baseline level of 
BMI (16.69), restrictive AN and no previous hospital admissions. 
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Table 2. Estimated outcome differences between treatment arms at 6 and 12 months post randomization. (Results are derived by 
multiple imputation.)  
 6 months after randomization 12 months after randomization 
Outcome Estimated 
group 
differenceǂ 
Test 95% 
confidence 
intervalǂ 
Standardised 
coefficientǂǂ 
Estimated 
group 
differenceǂ 
Test 95% confidence 
intervalǂ 
Standardised 
coefficientǂǂ 
BMI (kg / m2)P 0.26 z=0.85, 
p=0.39 
-0.34, 0.85 0.21 0.39 z=0.95, 
p=0.34 
-0.42, 1.20 0.31 
Weight (kg) 0.62 z=0.74, 
p=0.46 
-1.03, 2.27 0.13 0.82 z=0.72, 
p=0.47 
-1.41, 3.04 0.17 
Eating Disorder Examination 0.10 z=0.50, 
p=0.62 
-0.30, 0.51 0.08 -0.25 z=-1.04, 
p=0.30 
-0.73, 0.22 -0.19 
EDE restraint subscale 0.03 z=0.11, 
p=0.91 
-0.48, 0.54 0.02 -0.21 z=-0.66, 
p=0.51 
-0.85, 0.42 -0.14 
EDE eating concern subscale -0.03 z=-0.14, 
p=0.89 
-0.49, 0.42 -0.02 -0.41 z=-1.49, 
p=0.14 
-0.94, 0.13 -0.29 
EDE shape concern subscale 0.17 z=0.64, 
p=0.52 
-0.35, 0.69 0.10 -0.09 z=-0.35, 
p=0.73 
-0.62, 0.43 -0.05 
EDE weight concern subscale 0.06 z=0.21, 
p=0.83 
-0.49, 0.61 0.04 -0.34 z=-1.18, 
p=0.24 
-0.92, 0.23 -0.21 
Depression, Anxiety and Stress Scale -0.12 z=-0.05, 
p=0.96 
-4.63, 4.40 -0.01 1.04 z=0.44, 
p=0.66 
-3.65, 5.73 0.08 
Obsessive Compulsive Inventory-
Revised 
1.36 z=0.64, 
p=0.52 
-2.79, 5.52 0.10 0.56 z=0.24, 
p=0.81 
-4.13, 5.26 0.04 
Clinical Impairment Assessment -0.25 z=-0.13, 
p=0.90 
-3.93, 3.43 -0.03 -1.46 z=-0.65, 
p=0.52 
-5.90, 2.97 -0.16 
Wisconsin Card Sorting Task; 
Perseverative errors (log)* 
0.95 z=0.39, 
p=0.70 
0.74, 1.23 -0.07 0.83 z=1.56, 
p=0.12 
0.66, 1.05 -0.26 
Brixton Spatial Anticipation Task; 
Total errors 
0.10 z=0.13, 
p=0.90 
-1.38, 1.58 0.02 >-0.01 z>-0.01, 
p>0.99 
-2.82, 2.82 >-0.01 
Rey-Osterrieth Complex Figure Test; 
Central Coherence Index 
0.05 z=0.79, 
p=0.43 
-0.08, 0.18 0.18 0.05 z=0.76, 
p=0.45 
-0.08, 0.17 0.18 
Reading the Mind in Films Task 0.87 z=1.49, 
p=0.14 
-0.28, 2.03 0.32 0.68 z=1.09, 
p=0.28 
-0.55, 1.90 0.25 
ǂ coefficients represent estimated treatment effect of MANTRA – SSCM.  
ǂǂ standardised coefficients were derived by dividing estimated differences by respective baseline standard deviations 
* analysed on the log-scale, estimates represent factor change
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Table 3. Predicted mean outcomes (standard errors) by treatment arm and post-randomization time point*. (Results are derived by 
multiple imputation.)   
 6 months after randomization 12 months after randomization 
 SSCM MANTRA SSCM MANTRA 
Outcome Estimated 
mean 
Standard 
error 
Estimated 
mean 
Standard 
error 
Estimated 
mean 
Standard 
error 
Estimated 
mean 
Standard 
error 
BMI (kg / m2) 
[16.61] 
17.41 0.25 17.67 0.26 18.05 0.36 18.44 0.36 
Weight (kg) 
[45.07] 
47.16 0.69 47.78 0.71 48.94 0.96 49.76 1.00 
Eating Disorder Examination 
[3.30] 
2.68 0.17 2.78 0.19 2.45 0.20 2.20 0.23 
EDE restraint subscale 
[3.73] 
2.74 0.24 2.77 0.24 2.53 0.32 2.32 0.33 
EDE eating concern subscale 
[2.84] 
2.28 0.20 2.25 0.21 2.08 0.25 1.67 0.25 
EDE shape concern subscale 
[3.50] 
2.99 0.22 3.16 0.24 2.67 0.22 2.57 0.24 
EDE weight concern subscale 
[3.15] 
2.62 0.23 2.68 0.24 2.44 0.24 2.09 0.25 
Depression, Anxiety and Stress Scale 
[30.51] 
24.92 1.85 24.80 2.11 22.15 2.03 23.20 2.36 
Obsessive Compulsive Inventory-
Revised 
[23.56] 
20.79 1.66 22.15 1.96 19.84 1.84 20.40 2.26 
Clinical Impairment Assessment 
[32.56] 
25.65 1.69 25.40 1.85 22.38 1.90 20.92 2.14 
Wisconsin Card Sorting Task 
[7.77] 
6.35 0.81 6.04 0.68 7.82 1.14 6.51 0.94 
Brixton Spatial Anticipation Task 
[12.30] 
10.37 0.79 10.47 0.79 11.38 1.89 11.38 1.86 
Rey-Osterrieth Complex Figure Test 
[1.29] 
1.31 0.06 1.36 0.05 1.45 0.08 1.50 0.07 
 39 
Reading the Mind in Films Task 
[13.03] 
13.15 0.62 14.02 0.59 13.34 0.74 14.02 0.66 
* Mean outcomes were predicted for patients with sample average baseline levels (shown in [] in the left column, and from the most frequent 
stratifier categories (baseline BMI>15,  AN-subtype=AN-restrictive, no previous admission)).    
 
